Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways

Saved in:
Bibliographic Details
Main Authors: Yang Li, Zhichao Xi, Xiaoqiong Chen, Shuangfan Cai, Chen Liang, Zhen Wang, Yingyi Li, Hongsheng Tan, Yuanzhi Lao, Hongxi Xu
Format: Article
Language:English
Published: Nature Publishing Group 2025-04-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-025-07495-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850172966734659584
author Yang Li
Zhichao Xi
Xiaoqiong Chen
Shuangfan Cai
Chen Liang
Zhen Wang
Yingyi Li
Hongsheng Tan
Yuanzhi Lao
Hongxi Xu
author_facet Yang Li
Zhichao Xi
Xiaoqiong Chen
Shuangfan Cai
Chen Liang
Zhen Wang
Yingyi Li
Hongsheng Tan
Yuanzhi Lao
Hongxi Xu
author_sort Yang Li
collection DOAJ
format Article
id doaj-art-3949f5b57e5d4d3f81510a8334730c19
institution OA Journals
issn 2041-4889
language English
publishDate 2025-04-01
publisher Nature Publishing Group
record_format Article
series Cell Death and Disease
spelling doaj-art-3949f5b57e5d4d3f81510a8334730c192025-08-20T02:19:57ZengNature Publishing GroupCell Death and Disease2041-48892025-04-011611610.1038/s41419-025-07495-2Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathwaysYang Li0Zhichao Xi1Xiaoqiong Chen2Shuangfan Cai3Chen Liang4Zhen Wang5Yingyi Li6Hongsheng Tan7Yuanzhi Lao8Hongxi Xu9School of Pharmacy, Shanghai University of Traditional Chinese MedicineSchool of Pharmacy, Shanghai University of Traditional Chinese MedicineSchool of Pharmacy, Shanghai University of Traditional Chinese MedicineSchool of Pharmacy, Shanghai University of Traditional Chinese MedicineCancer Research Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityCancer Research Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityCancer Research Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversitySchool of Pharmacy, Shanghai University of Traditional Chinese MedicineSchool of Pharmacy, Shanghai University of Traditional Chinese MedicineSchool of Pharmacy, Shanghai University of Traditional Chinese Medicinehttps://doi.org/10.1038/s41419-025-07495-2
spellingShingle Yang Li
Zhichao Xi
Xiaoqiong Chen
Shuangfan Cai
Chen Liang
Zhen Wang
Yingyi Li
Hongsheng Tan
Yuanzhi Lao
Hongxi Xu
Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
Cell Death and Disease
title Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
title_full Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
title_fullStr Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
title_full_unstemmed Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
title_short Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
title_sort correction to natural compound oblongifolin c confers gemcitabine resistance in pancreatic cancer by downregulating src mapk erk pathways
url https://doi.org/10.1038/s41419-025-07495-2
work_keys_str_mv AT yangli correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT zhichaoxi correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT xiaoqiongchen correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT shuangfancai correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT chenliang correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT zhenwang correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT yingyili correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT hongshengtan correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT yuanzhilao correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways
AT hongxixu correctiontonaturalcompoundoblongifolincconfersgemcitabineresistanceinpancreaticcancerbydownregulatingsrcmapkerkpathways